CD4 and pneumocystosis: The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) has shown that primary Pneumocystis jirovecii Pneumonia (PjP) prophylaxis can be safely withdrawn in patients with CD4 counts of 100 to 200 cells/μL if plasma HIV‐RNA is suppressed on combination antiretroviral therapy.